Smartlens, a Mountain View, CA-based clinical-stage ophthalmic technology company, raised $6.1M in Series A funding.
The round was led by Ambit Health Ventures, joined by Stanford University, Graphene Ventures, Sophia Innovation Capital, Plaisance Capital Management, 3E Bioventures, Boutique Venture Partners and Wilson Sonsini Investments.
Led by Savas Komban, CEO, Smartlens specializes in developing innovative solutions for diagnosing and treating chronic eye diseases.
The company intends to use the funds to advance regulatory clearance for miLens, a novel, electronics-free, soft contact lens for monitoring diurnal intraocular pressure (IOP).
This device is an electronics free soft contact lens that uses microfluidics technology. It enables monitoring of intraocular pressure (IOP) outside of clinical settings for individuals with glaucoma and ocular hypertension.
FinSMEs
11/07/2023